BioProject

Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL) represent 15% and 20%, respectively, of all lymphoma types. Diagnosis depends on pathological evaluation; however, in cases lacking biopsy tissue, diagnostic biomarkers might substitute for pathological assessment. The aim of this study was to identify and compare circulating serum miRNA (c-miRNA) and peripheral whole blood miRNA (wb-miRNA) profiles in patients with HL or DLBCL. Serum samples (20 HL, 21 DLBCL, and 30 healthy controls) and whole blood samples (23 HL, 20 DLBCL patients, and 30 healthy controls) were collected at the time of diagnosis. Serum and whole blood was also collected from 18 HL/17 DLBCL and eight HL/nine DLBCL patients, respectively, after treatment. MiRNAs were sequenced using an Ion Proton sequencer.Pair-wise comparisons identified 125 c-miRNAs (adjusted P-value < 0.05) showing significant dysregulation between 30 healthy controls and patients; of these, 47 and 55 differentiated controls from pre‑therapeutic HL and DLBCL patients, respectively. In addition, 60 and 16 c-miRNAs differentiated controls from post‑therapeutic HL and DLBCL patients, respectively. Pair-wise comparisons identified 292 wb-miRNAs (adjusted P-value < 0.05) showing significant dysregulation between 30 controls and patients; of these, 103 and 169 differentiated controls from pre‑therapeutic HL and DLBCL patients, respectively, and 142 and 151 wb-miRNAs differentiated controls from post‑therapeutic HL and DLBCL patients, respectively.Profiles of dysregulated circulating and whole blood miRNAs differed significantly. Of 145 and 186 c-miRNAs and/or wb-miRNAs dysregulated in pre‑ and post-therapeutic HL patients, only five and 16, respectively, were common to both sets of miRNAs. A similar comparison performed among DLBCL patients revealed that 213 and 164 c-miRNAs and/or wb-miRNAs were dysregulated in pre- and post-therapeutic patients, respectively, of which 11 and three, respectively, were common to both miRNA sets.Thus, lymphoma-associated miRNAs may be a better source of noninvasive candidate biomarkers than miRNAs circulating in serum. It is unclear whether miRNA alterations in lymphoma cells are similar to those observed in white blood cells.